经皮血管介入与旁路手术治疗严重肢体缺血的荟萃分析
该荟萃分析纳入45个队列和1项随机对照试验、超过20,903例严重肢体缺血患者,比较经皮血管介入(PVI)与旁路手术(BSX)。PVI降低30天死亡率、主要不良心脑血管事件和手术部位感染风险,但增加长期全因死亡和原发通畅失败风险;与自体旁路相比,PVI还增加长期死亡或截肢及二期通畅失败风险。
要点
- PVI降低30天死亡率、主要不良心脑血管事件和手术部位感染风险。
- PVI增加长期全因死亡和原发通畅失败风险。
- 与自体旁路相比,PVI增加长期死亡或截肢及二期通畅失败风险。
核心结论
- 对于身体状况良好、预期寿命较长的患者,BSX可能优于PVI,尤其当可获得自体旁路时。
- 接受BSX的患者应考虑加强围术期心血管事件和手术部位护理,以实现与PVI相当的短期结局。
研究设计与样本
- 荟萃分析纳入所有比较PVI与BSX治疗CLI患者的随机对照试验和观察性临床研究。
- 共识别45个队列和1项随机对照试验,纳入超过20,903例患者。
- 主要终点包括总生存率、无截肢生存率、30天死亡率和主要不良心脑血管事件。
主要发现
- 在总体人群中,PVI降低30天死亡率(OR 0.69,95%CI 0.51-0.95)、主要不良心脑血管事件(OR 0.42,95%CI 0.29-0.61)和手术部位感染(OR 0.31,95%CI 0.19-0.51)风险。
- PVI增加长期全因死亡(HR 1.16,95%CI 1.05-1.27)和原发通畅失败(HR 1.31,95%CI 1.08-1.58)风险。
- 与自体BSX相比,PVI增加长期死亡或截肢(HR 1.41,95%CI 1.02-1.94)和二期通畅失败(HR 1.51,95%CI 1.17-1.95)风险。
- 在膝下病变患者中,PVI的原发通畅性劣于BSX(HR 1.39,95%CI 1.10-1.75)。
临床怎么用
- 对于身体状况良好、预期寿命较长的CLI患者,尤其当可获得自体旁路时,BSX可能是更好的选择。
- 接受BSX的患者应加强围术期心血管事件和手术部位感染的防治,以弥补短期结局劣势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of our study was to compare percutaneous vascular interventions (PVI) versus bypass surgeries (BSX) in patients with critical limb ischemia (CLI). BACKGROUND: Previous relevant reviews with limited numbers of included studies did not strictly confine the inclusion criteria to CLI, also involving patients with severe claudication, which may introduce bias in the decision-making of CLI revascularization. Current treatment strategies for CLI still remain controversial. METHODS: We performed a meta-analysis of all available randomized controlled trials and observational clinical studies comparing PVI with BSX in CLI patients. Primary endpoints included overall survival, amputation-free survival, 30-day mortality, and major adverse cardiovascular and cerebrovascular events. RESULTS: We identified 45 cohorts and 1 RCT in over 20,903 patients. In overall population, PVI reduced the risks of 30-day mortality [odds ratio (OR) 0.69, 95% confidence interval (CI) 0.51-0.95), major adverse cardiovascular and cerebrovascular events (OR 0.42, 95% CI 0.29-0.61), and surgical site infection (OR 0.31, 95% CI 0.19-0.51), but increased the risks of long-term all-cause mortality [hazard ratio (HR) 1.16, 95% CI 1.05-1.27) and primary patency failure (HR 1.31, 95% CI 1.08-1.58). When compared with autogenous BSX, PVI was also associated with additional increased risks of long-term death or amputation (HR 1.41, 95% CI 1.02-1.94) and secondary patency failure (HR 1.51, 95% CI 1.17-1.95). In patients with infrapopliteal lesions, we found PVI had inferior primary patency (HR 1.39, 95% CI 1.10-1.75) compared with BSX. CONCLUSION: For patients in good physical condition with long life-expectancy, BSX may represent a better choice compared with PVI, particularly when autogenous bypass is available. While enhanced perioperative care for cardiovascular events and surgical site should be considered in patients underwent BSX to achieve comparable short-term outcomes provided by PVI.
引用
- Wang J, Shu C, Wu Z, et al. Percutaneous Vascular Interventions Versus Bypass Surgeries in Patients With Critical Limb Ischemia: A Comprehensive Meta-analysis. Ann Surg. 2018. PMID: 28654542. doi:10.1097/SLA.0000000000002344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。